Method for the Treatment of a Relapsing-Remitting Condition
AssigneeImmune Regulation Limited
InventorsAndrew Lightfoot, Nicola Cooper, Donata Federici Canova
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for the acute treatment of a relapsing-remitting condition, the method comprising the step of administering to a subject in need thereof one or more doses of an effective amount of a peptide molecule as defined in claim 1 in response to or during a relapse, wherein the method causes remission of the condition.
Claims39
A method for the acute treatment of a relapsing-remitting condition, the method comprising the step of administering to a subject in need thereof one or more doses of an effective amount of a peptide molecule comprising or consisting of an amino acid sequence selected from one of the group (i) to (xv):
- (i)
- (SEQ ID NO:
- 1)
- DGSVVVNKVSELPAGHGLNVNTLSYGDLAAD;
- (ii)
- (SEQ ID NO:
- 2)
- XHGLNVNTLSYGD
- wherein X is absent or is selected from the group consisting of a beta alanine residue, 9-amino-3,6-dioxaoctanoic acid, and an acetyl group;
- or variants thereof comprising one or more of i(i) to i(iii);
- ii(i) one or more amino acid residues are in the D conformation, ii(ii) GLNVNTLSYGD is inverted, or ii(iii) the carboxyl terminal amino acid residue is converted to a primary carboxamide group;
- (iii)
- (SEQ ID NO:
- 3)
- DGSVVVNKVSEL-NH2;
- (iv)
- (SEQ ID NO:
- 4)
- SELPAGHGLNVNTLSYGDLAAD;
- (v)
- (SEQ ID NO:
- 5)
- SELPAGHGLNVNTLS;
- (vi)
- (SEQ ID NO:
- 6)
- PAGHGLNVNTLS-NH2;
- (vii)
- (SEQ ID NO:
- 7)
- VVVNKVSELPAGHGLNVNTLSYGDLAAD;
- (viii)
- (SEQ ID NO:
- 8)
- NKVSELPAGHGLNVNTLSYGDLAAD;
- (ix)
- (SEQ ID NO:
- 9)
- PAGHGLNVNTLSYGDLAAD;
- (x)
- (SEQ ID NO:
- 10)
- HGLNVNTLSYGDLAAD;
- (xi)
- (SEQ ID NO:
- 11)
- DGSVVVNKVSELPAGH;
- (xii)
- (SEQ ID NO:
- 12)
- GLNVNTLSYGDLAAD;
- (xiii)
- (SEQ ID NO:
- 13)
- DGSVVVNKVS;
- (xiv)
- (SEQ ID NO:
- 14)
- NTLSYGDLAAD;
- and
- (xv) a polypeptide sequence which has more than 85% or 90% or 95% identity to any of (i) to (xiv) and has a function equivalent to any of (i) to (xiv);
- in response to or during a relapse, wherein the method causes remission of the condition.
A method according to any preceding claim which causes disease modification.
A method according to any preceding claim, wherein remission is maintained without the need for the administration of further doses of the peptide.
A method according to any preceding claim, wherein remission comprises the reduction, alleviation or elimination of one or more symptoms of the condition.
A method according to any preceding claim, wherein remission comprises the reduction, alleviation or elimination of one or more symptoms of the condition for a period of time which significantly exceeds the plasma pharmacokinetic half-life of the peptide.
A method according to any preceding claim wherein remission is maintained when the plasma peptide concentration is below the lower limit of quantification.
A method according to any preceding claim, wherein remission of the condition is for a period of at least 7 days after the concentration of the peptide molecule in the plasma of the subject is below the lower limit of quantification.
A method according to any preceding claim, wherein remission of the condition is for a period of at least 7 days after administration of the final dose of the peptide.
A method according to any preceding claim, wherein remission of the condition is for a period of at least 14 days after administration of the final dose of the peptide.
A method according to any preceding claim, wherein remission of the condition is for a period of at least 28 days after administration of the final dose of the peptide.
A method according to any preceding claim, wherein remission of the condition is for a period of at least 6 months after administration of the final dose of the peptide.
A method according to any preceding claim, wherein a single dose of the peptide is administered to the human subject.
A method according to any preceding claim, wherein the condition is an inflammatory condition.
A method according to any preceding claim, wherein the condition is selected from the group consisting of asthma, Crohn's disease, allergic inflammatory conditions such as atopic dermatitis and rhinitis, rheumatoid arthritis and inflammatory bowel disease.
A method according to any preceding claim, wherein the condition is associated with eosinophilia and/or neutrophilia.
A method according to any preceding claim, wherein remission comprises a significant reduction in the number of lymphocytes or a significant increase in the number of macrophages in the human subject relative to a control subject.
A method according to any preceding claim, wherein remission comprises a significant change in the amount of one or more inflammatory markers such as cytokines, for example IL-4, IL-5, IL-10 or IL-13 in the human subject relative to a control subject.
A method according to any preceding claim, wherein remission comprises a significant increase in the amount of IL-10 in the human subject relative to a control subject.
A method according to any preceding claim, wherein remission comprises a significant reduction in the amount of IL-4, IL-5 or IL-13 in the human subject relative to a control subject.
A method according to any preceding claim, wherein relapse of the condition comprises an increase in the number or severity of the symptoms associated with the condition.
A peptide molecule as defined in any preceding claim for use in a method as defined in any preceding claim.
A pharmaceutical composition comprising a peptide molecule as defined in any preceding claim and one or more pharmaceutically acceptable excipients for use in a method as defined in any preceding claim.
A method, peptide for use or pharmaceutical composition according to any preceding claim wherein the patient is further administered one or more therapeutic agents or when the peptides are provided in combination with one or more therapeutic agents.
Dependencies are inferred from the claim text.